Table 2.
Rate Ratios for selected cancers by intensity-weighted lifetime exposure days (IWED) to imazethapyr among AHS participants, 1993-2004a
| Cancer Site | IWED | Cases | Multivariate Adjusted RR (95% CI) |
|---|---|---|---|
| All Cancers b | No Exposure | 1919 | 1.00 |
| T1 | 328 | 0.95 (0.84, 1.07) | |
| T2 | 318 | 1.02 (0.91, 1.16) | |
| T3 (lower half) | 172 | 1.00 (0.86, 1.18) | |
| T3 (upper half) | 170 | 1.13 (0.96, 1.34) | |
| p for trend | 0.14 | ||
| Prostate c | No Exposure | 745 | 1.00 |
| T1 | 148 | 1.04 (0.87, 1.25) | |
| T2 | 136 | 1.04 (0.87, 1.26) | |
| T3 (lower half) | 73 | 1.05 (0.82, 1.35) | |
| T3 (upper half) | 59 | 1.06 (0.81, 1.40) | |
| p for trend | 0.97 | ||
| Lung d | No Exposure | 212 | 1.00 |
| T1 | 30 | 1.24 (0.82, 1.88) | |
| T2 | 21 | 0.92 (0.57, 1.50) | |
| T3 (lower half) | 11 | 1.05 (0.56, 1.97) | |
| T3 (upper half) | 11 | 1.01 (0.54, 1.88) | |
| p for trend | 0.92 | ||
| Colon e | No Exposure | 141 | 1.00 |
| T1 | 22 | 0.90 (0.57, 1.41) | |
| T2 | 26 | 1.20 (0.79, 1.85) | |
| T3 (lower half) | 13 | 1.09 (0.61, 1.95) | |
| T3 (upper half) | 18 | 1.78 (1.08, 2.93) | |
| p for trend | 0.02 | ||
| Rectum f | No Exposure | 73 | 1.00 |
| T1 | 14 | 1.04 (0.58, 1.86) | |
| T2 | 12 | 0.97 (0.52, 1.81) | |
| T3 (lower half) | 10 | 0.77 (0.39, 1.51) | |
| p for trend | 0.81 | ||
| Melanoma g | No Exposure | 64 | 1.00 |
| T1 | 11 | 0.85 (0.45, 1.61) | |
| T2 | 16 | 1.36 (0.78, 2.36) | |
| T3 (lower half) | 10 | 1.38 (0.71, 2.71) | |
| T3 (upper half) | 7 | 1.08 (0.49, 2.37) | |
| p for trend | 0.58 | ||
| Bladder h | No Exposure | 81 | 1.00 |
| T1 | 12 | 0.99 (0.53, 1.83) | |
| T2 | 10 | 0.94 (0.48, 1.83) | |
| T3 (lower half) | 7 | 1.29 (0.58, 2.86) | |
| T3 (upper half) | 12 | 2.37 (1.20, 4.68) | |
| p for trend | 0.01 | ||
| All lymphohematopoietic i | No Exposure | 187 | 1.00 |
| T1 | 29 | 0.71 (0.47, 1.07) | |
| T2 | 30 | 0.78 (0.52, 1.17) | |
| T3 (lower half) | 17 | 0.77 (0.46, 1.30) | |
| T3 (upper half) | 23 | 1.23 (0.77, 1.98) | |
| p for trend | 0.41 | ||
| Leukemia j | No Exposure | 63 | 1.00 |
| T1 | 9 | 0.76 (0.38, 1.54) | |
| T2 | 12 | 1.21 (0.65, 2.27) | |
| T3 (lower half) | 6 | 1.15 (0.49, 2.71) | |
| T3 (upper half) | 7 | 1.63 (0.72, 3.69) | |
| p for trend | 0.19 | ||
| NHL k | No Exposure | 80 | 1.00 |
| T1 | 15 | 0.95 (0.55, 1.66) | |
| T2 | 13 | 0.91 (0.50, 1.64) | |
| T3 (lower half) | 7 | 0.83 (0.34, 1.80) | |
| T3 (upper half) | 11 | 1.44 (0.76, 2.74) | |
| p for trend | 0.35 | ||
| Kidney l | No Exposure | 58 | 1.00 |
| T1 | 7 | 0.61 (0.28, 1.34) | |
| T2 | 11 | 1.07 (0.56, 2.06) | |
| T3 | 10 | 0.91 (0.46, 1.79) | |
| p for trend | 0.39 | ||
| Oral Cavity m | No Exposure | 45 | 1.00 |
| T1 | 12 | 1.50 (0.78, 2.88) | |
| T2 | 8 | 1.07 (0.49, 2.30) | |
| T3 | 7 | 0.82 (0.36, 1.85) | |
| p for trend | 0.70 | ||
| Pancreas n | No Exposure | 34 | 1.00 |
| T1 | 5 | 0.80 (0.31, 2.05) | |
| T2 | 6 | 1.07 (0.44, 2.55) | |
| T3 | 7 | 1.20 (0.52, 2.74) | |
| p for trend | 0.74 |
Abbreviations (alphabetical): Agricultural Health Study (AHS); Confidence Interval (CI); Rate Ratio (RR). IWED categories are defined as: <54.1 (T1), 54.1 to <152.9 (T2), 152.9 to <311.9 (T3 lower half), and ≥ 311.9 (T3 upper half).
Adjusted for age at and year of enrollment.
Additionally adjusted for race, family history of cancer, smoking status, applicator type, alachlor, and lifetime days of pesticide exposure.
Additionally adjusted for race, family history of prostate cancer, applicator type, alachlor, and carbofuran use.
Additionally adjusted for state, smoking status, and education level.
Additionally adjusted for race, chlorpyrifos, and aldicarb.
Additionally adjusted for smoking status, alcohol intake, aldicarb, chlorpyrifos, pendimethalin, and permethrin use.
Additionally adjusted for race and family history of any cancer.
Additionally adjusted for race, applicator type, smoking status, and metolachlor.
Includes non-Hodgkin lymphoma, Hodgkin lymphoma, leukemia, and multiple myeloma. Additionally adjusted for alcohol intake and atrazine use.
Additionally adjusted for lifetime days of pesticide exposure.
Additionally adjusted for race.
Additionally adjusted for gender and family history of any cancer.
Additionally adjusted for race, gender, alcohol intake, and smoking status.
Additionally adjusted for smoking status, and family history of any cancer.